Four things to know · April 15, 2026
DSIP
Delta Sleep-Inducing Peptide (Emideltide)
DSIP (Delta Sleep-Inducing Peptide, listed by the FDA as Emideltide) is a short, naturally occurring peptide first isolated from the blood of sleeping rabbits in 1974.
Noticed in days · Full benefit in weeks
First dose
Noticeable sleep pressure and easier sleep onset, typically 30-60 minutes after injection.
Night 1-3
Deeper sleep, fewer night awakenings. Vivid dreams are commonly reported.
Day 2-5
Improved morning refreshment and more stable daytime energy.
Day 5-10
Cumulative stress reduction and mood stabilization. Effects often persist 1-2 weeks after the cycle ends.
DSIP (Delta Sleep-Inducing Peptide, listed by the FDA as Emideltide) is a short, naturally occurring peptide first isolated from the blood of sleeping rabbits in 1974. It's the oldest compound on the FDA's July 2026 review agenda by date of discovery. Unlike traditional sleep drugs, DSIP doesn't sedate. It works with your body's own sleep architecture, deepening slow-wave sleep rather than forcing unconsciousness. Half a century after its discovery, the research base is small but distinctive: modest human trial data for insomnia, plus a niche Russian-era body of work on opioid withdrawal and chronic pain.
How it works
DSIP modulates several neurotransmitter systems at once. It enhances GABA signaling (your brain's primary calming chemical), interacts with NMDA receptors, and engages the endogenous opioid system. It also helps regulate the HPA axis, your body's stress-response pathway, which is why people commonly report both better sleep and lower daytime stress. The nasal route adds a second pathway: olfactory transport that delivers the peptide directly into the central nervous system, producing faster onset than subcutaneous injection.
Key benefits
What early research points to:
- ·Enhances deep slow-wave sleep without sedation
- ·Shortens time to fall asleep and reduces night awakenings
- ·Calms the stress response by modulating cortisol and the HPA axis
- ·No tolerance, dependence, or withdrawal reported across 50 years of research
- ·Supports natural sleep architecture rather than forcing unconsciousness
- ·Under FDA review for insomnia, opioid withdrawal, and narcolepsy
Related goals
Regulatory status
Category 2 (listed by the FDA as Emideltide). The FDA's pharmacy compounding advisory committee is scheduled to review DSIP on July 24, 2026, for potential addition to the 503A bulks list. The uses under review: opioid withdrawal, chronic insomnia, and narcolepsy. Originally discovered in 1974, one of the oldest peptides on the July 2026 agenda.
Journal · July 2026 PCAC
What the peptide panel is really voting on →
Injection
most studiedThe route used in the 1991 double-blind human insomnia trial and most of the Russian-era withdrawal and pain research. Subcutaneous DSIP produces the classic slow-wave sleep effects and longer-lasting stress modulation. Onset is slower than nasal but effects persist longer, and the benefits often linger for a week or two after stopping.
Injection protocols
| Protocol | Dose | Frequency |
|---|---|---|
| Sleep enhancement | 100-200mcg | Once nightly |
| Chronic pain support | 250-300mcg | Once daily |
| Stress management | 150mcg | Evening |
| Withdrawal support (clinical) | 200-300mcg | Twice daily |
Protocols are from published research literature. This is not medical advice. Dosing should be determined by a licensed clinician.
What people report
Noticeable sleep pressure and easier sleep onset, typically 30-60 minutes after injection.
Deeper sleep, fewer night awakenings. Vivid dreams are commonly reported.
Improved morning refreshment and more stable daytime energy.
Cumulative stress reduction and mood stabilization. Effects often persist 1-2 weeks after the cycle ends.
What to know
- ⚠Start at 100mcg to gauge your response before increasing
- ⚠Some users report mild drowsiness or dizziness initially. Avoid driving until you know how you respond
- ⚠Occasional headaches have been reported in sensitive individuals
- ⚠No tolerance or dependence reported across five decades of research
- ⚠Use caution if combining with opioid medications or GABA-active drugs
- ⚠Not recommended during pregnancy or breastfeeding
- ⚠DSIP has limited stability. Refrigerate and use reconstituted solution within 14 days
KEY RESEARCH · 5 PAPERS CITED
Schneider-Helmert D, Schoenenberger GA
Experientia
1983
Kovalzon VM, Strekalova TV
Journal of Neurochemistry
2006
Graf MV, Kastin AJ
Peptides
1984
Research team (PCAC docket)
PCAC FDA-2025-N-6895
2021
Multiple
Neuroendocrinology
1988
The Pep Dispatch
Follow the evidence on DSIP as it evolves.
Subscribe to find out what.
Next dispatch · May 2026 · Honest frequency: a few times a month
For the people who want to feel better — not just look up symptoms.